Edition:
United States

Alkermes Plc (ALKS.O)

ALKS.O on Nasdaq

56.83USD
9:43am EST
Change (% chg)

$-1.44 (-2.47%)
Prev Close
$58.27
Open
$57.00
Day's High
$57.50
Day's Low
$56.43
Volume
66,711
Avg. Vol
1,068,687
52-wk High
$80.71
52-wk Low
$27.14

Select another date:

Thu, Nov 3 2016

BRIEF-Alkermes inspiration grants awarded to support people affected by mental health and substance use disorders

* Alkermes inspiration grants(tm) awarded to support people affected by mental health and substance use disorders Source text for Eikon: Further company coverage:

BRIEF-Alkermes Q3 loss per share $0.41

* Alkermes plc qtrly royalty revenue from Bydureon was $11.6 million, compared to $13.0 million for same period in prior year

U.S. RESEARCH ROUNDUP-Alkermes, Chesapeake Energy Corp, Latam Airlines

Oct 21 Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Alkermes, Benchmark Electronics and Copa Holdings on Friday. HIGHLIGHTS * Chesapeake Energy Corp : Nomura raises to neutral from reduce * Latam Airlines : Santander raises to buy from hold * Proofpoint Inc : Piper Jaffray raises target price to $90 from $85; overweight Following is a sum

Alkermes depression drug succeeds in key trial; shares surge

Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

UPDATE 2-Alkermes depression drug succeeds in key trial; shares surge

Oct 20 Alkermes Plc's experimental depression drug significantly reduced symptoms in patients suffering from major depressive disorder who were not helped by standard treatments in a pivotal late-stage trial, the company said on Thursday, and its shares surged 47 percent.

Alkermes depression drug meets main goal; shares surge

Oct 20 Alkermes Plc said its lead depression drug met the main goal of a late-stage trial, sending its shares up 48 pct in extended trading.

BRIEF-Alkermes announces topline results from phase 3 study of Alks 5461

* Alkermes announces positive topline results from forward-5 pivotal phase 3 study of alks 5461 for major depressive disorder

BRIEF-Alkermes, certain subsidiaries enter into amendment to amended, restated credit agreement

* Alkermes - On Oct. 12, co, certain other subsidiaries of company entered into an amendment to amended and restated credit agreement - SEC filing

BRIEF-Alkermes submits supplemental new drug application to FDA

* Alkermes submits supplemental new drug application to FDA for two month dosing option of Aristada for treatment of schizophrenia

Select another date: